The Lisbon Cohort of men who have sex with men.

PURPOSE: Newly diagnosed HIV infections among men who have sex with men (MSM) are rising in many European countries. Surveillance tools must be tailored to the current state of the epidemic, and include decentralised prospective monitoring of HIV incidence and behavioural changes in key populations. In this scenario, an open prospective cohort study was assembled--The Lisbon Cohort of MSM--aiming to dynamically monitor the frequency of disease and its predictors. PARTICIPANTS: The Lisbon Cohort of MSM is an ongoing observational prospective study conducted at a community-based voluntary HIV counselling and testing centre in Lisbon, Portugal (CheckpointLX). Men testing negative for HIV, aged 18 or over and reporting having had sex with men are invited to follow-up visits every 6 months. At each evaluation, a face-to-face interview using a structured questionnaire is conducted, and HIV and syphilis rapid tests are performed by trained peer counsellors. From April 2011 to February 2014, 3106 MSM were eligible to the cohort of whom 923 (29.7%) did not participate. The remaining 2183 (70.3%) MSM were enrolled and 804 had at least one follow-up evaluation, for a total of 893 person-years of observation. FUTURE PLANS: The study findings will be disseminated in peer-reviewed journals and presented at national and international conferences. The follow-up of this cohort of HIV-negative MSM will be a valuable tool for monitoring HIV incidence in a setting where limited prospective information existed. Moreover, it will allow for a deeper analytical approach to the study of population time trends and individual changes in risk factors that currently shape the HIV epidemic among MSM. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Enables the dynamic monitoring of the frequency of the disease and its predictors.

Enables the comparison of the findings with other cohorts.

Limited representativeness of the sample.

Selection and participation bias.

Possible Hawthorne effect.

Introduction

Since the beginning of the HIV/AIDS epidemic in the early 80s, gay, bisexual and other men who have sex with men (MSM) have been a core population affected by the disease, but also key contributors to the response to it.1 2 During the past three decades, significant scientific advances and societal efforts in the fields of prevention, treatment, care and support have renewed the hope of achieving an AIDS-free generation. However, in many high-income countries where a decline in overall HIV diagnoses have been observed, a concurrent increase in the number of new cases among MSM has also been documented.3 In the European Union/European Economic Area (EU/EEA) the largest increase in new diagnoses in the last decade was observed among young MSM, aged 20–29 years old.4

In Portugal, as in most EU/EEA countries, the HIV epidemic is concentrated in certain key populations, such as MSM, people who inject drugs, prisoners and commercial sex workers.5 A large internet survey on Portuguese MSM found a prevalence of self-reported HIV infection of 10.9% among participants with a previous HIV test.6 Although with different methodology, a previous interview survey found a very similar prevalence of 10.3% of self-reported HIV infection among participants ever tested (Gama A, 2013, personal communication).

Portuguese official surveillance data show a 9% annual increase in the number of newly diagnosed HIV cases among MSM from 2005 to 2012, while cases due to unsafe injection behaviour and heterosexual intercourse decreased by 18% and by 2%, respectively, in the same period.7 In 2013, sex between men accounted for 42.9% of all HIV cases reported in men and 30.3% of all cases.7 Hence, there is an urgency to establish dynamic instruments to monitor HIV incidence and determinants in this population if, in fact, we want to succeed in the response to HIV among MSM.1

HIV surveillance must be tailored to the state of the epidemic in each setting, and this includes the promotion of decentralised surveillance tools that are capable of capturing HIV trends and behavioural changes in a more timely and analytical fashion than national surveillance systems, which are necessarily heavier structures with a resulting limited applicability for behavioural research.8

Community-based studies of MSM present great challenges, namely when it comes to defining a sampling frame,9 due to the clear difficulty in establishing the boundaries of the target population itself because of cultural, anthropological and sociological reasons. Traditional sampling strategies designed to ensure representativeness and external validity, such as simple, random or cluster sampling, are often not efficient enough to recruit and follow MSM.8–11 Alternative sampling techniques such as convenience sampling in community-based facilities devoted to MSM can be substantially more feasible and improve crucial attributes for the success of integrated epidemiological surveillance such as simplicity, acceptability of participants and stability.8–12

The Lisbon Cohort of MSM was assembled as a facility-based open prospective cohort in a community-based voluntary HIV counselling and testing service directed at MSM. The main objectives of the study are: on a first stage, to quantify the frequency of the disease by estimating the incidence of HIV infection in MSM, and monitoring trends in primary (condom use for anal intercourse (AI)) and secondary prevention (early detection); and, in a subsequent stage, to identify strategies to improve the provision of HIV testing.

Cohort description

The Lisbon Cohort of MSM is an ongoing observational prospective study established in April 2011, designed as an open cohort. Eligible participants are MSM, aged 18 or older, regardless of nationality or residence, who voluntarily attend CheckpointLX for HIV testing and counselling, and who have a negative HIV test result at the time of recruitment.

Setting

The cohort is a joint project of GAT Portugal (GAT) and the Institute of Public Health of the University of Porto (ISPUP). GAT is a non-governmental organisation advocating legal and political changes that can have a positive effect on the rights and quality of life of those living with HIV, or those most at risk of acquiring the infection. One of GAT's projects has materialised in CheckpointLX, where the Lisbon Cohort of MSM is recruited. CheckpointLX is a community-based centre for anonymous and free rapid HIV testing and counselling, targeted at MSM, and provided by trained peer MSM counsellors. ISPUP is an advanced training and research institution in the Public Health domain. With respect to the cohort study, CheckpointLX is responsible for recruitment and data collection, while ISPUP provides scientific support, data management and analysis. Both institutions were involved in the design and implementation of the cohort protocol, and both have established an official partnership to guarantee a shared commitment to the follow-up of cohort participants, and to the periodic dissemination and evaluation of research outputs.

Ethics

The collected data are confidential, and the participants give their written informed consent prior to inclusion. Furthermore, in accordance with the ethical guidelines for surveillance in populations at higher risk for HIV, the Lisbon Cohort of MSM offers all participants: timely results, information about HIV and AIDS, counselling on HIV prevention and with regard to other health or social needs, linkage to treatment, and care to the extent possible with local resources and protocols with health services for referrals.9

Funding

From April 2011 to March 2014, there was no specific funding for this study. All direct costs with human resources and materials were supported through CheckpointLX as part of its daily activity. Since April 2014, additional specific funding has been obtained as part of the European Commission DG SANCO—Health and Consumers funded Euro HIV EDAT project (grant number 20131101). From inception, ISPUP has provided pro bono contribution through the allocation of research staff time and information technology support (programming, software and hardware) to the project.

Recruitment and follow-up of participants

Recruitment is generally made on the first visit to CheckpointLX, where peer counsellors invite all eligible individuals to enter the cohort. Eligibility criteria for entering the cohort are being a male aged 18 or over, regardless of nationality or residence, reporting having had sex with other men and having a HIV-negative test result. CheckpointLX is publicised in MSM socialising sites such as bars, discos, saunas, sex shops and guesthouses, parties and events of the gay community, cruising areas and online social networks. The centre itself, since it is located at a Lesbian Gay Bisexual Transgender socialising quarter, promotes walk-ins. Promotional materials include flyers, videos, stickers, banners at online social networks and prevention kits containing condoms, lubricant and an information card about CheckpointLX.

Follow-up is intended to take place at intervals of 6 months, although the exact time between visits is adjusted according to the convenience of the participant. Men who leave their contact details are invited to come back for follow-up visits through text messages or email from CheckpointLX staff. All the remaining participants are interviewed and tested for HIV whenever they decide to appear again for testing. Repeat visits are identified by asking if the individual has already been invited to enter the cohort. Most participants do not have trouble remembering if they are part of the cohort. However, if someone does not remember being enrolled in the cohort, the peer counsellor usually gives him some external cues.

End points for follow-up are the acquisition of HIV infection or death. Recruitment began almost 3 years ago; since then, we have followed 804 participants for a total of 893 person-years. Median time between visits was 208 days (approximately 7 months) and 25th–75th centiles were 148–308 days (approximately 5–10 months).

Study procedures

Questionnaire

At each visit, a face-to-face interview is performed by a trained CheckpointLX peer counsellor and data are recorded using a structured questionnaire. The questionnaire applied at cohort entry is divided into the following sections: sociodemographic characteristics, HIV testing history, sexual life and partners, condom use, use of alcohol and drugs, postexposure prophylaxis (PEP) and other sexually transmitted infections (STIs). Follow-up questionnaires update time-varying information on all sections. The questionnaire is provided as an online supplementary file; detailed content is presented in table 1.

Table 1

Content of the questionnaire

	Entry	Follow-up
1. Sociodemographic characteristics
Date of birth	✓	–
Gender	✓	–
Country of birth	✓	–
Educational level	✓	✓
Employment status	✓	–
2. HIV testing
Ever tested for HIV	✓	–
Access to HIV testing result	✓	–
Reasons for not testing or not having HIV test result	✓	–
Number of previous HIV tests	✓	–
Place, date and result of previous HIV test	✓	✓
Reasons for index test	✓	✓
3. Sexual life and partners
Sexual identity	✓	✓
Age at first anal intercourse	✓	–
Role in anal intercourse	✓	✓
Characteristics of sexual partners in the previous 12 months/since the previous visit*	✓	✓
A. Steady partner
Steady partner in the previous 12 months/since the previous visit	✓	✓
Duration of the relationship with steady partner	✓	✓
Gender of steady partner	✓	✓
Sexual practices with steady partner	✓	✓
Sexual intercourse with other partners	✓	✓
HIV status of the steady partner	✓	✓
B. Occasional partner
Occasional partner in the previous 12 months/since the previous visit	✓	✓
Number of occasional partners in the previous 12 months/since the previous visit	✓	✓
Sexual practices with an occasional partner	✓	✓
Venues used to meet occasional partners	✓	✓
C. Sex work
Having sex for money or drugs in the previous 12 months/since previous visit	✓	✓
4. Condom use
Condom use with a steady partner in the previous 12 months/since the previous visit	✓	✓
Condom use with a steady partner in the last anal intercourse	✓	✓
Condom use with an occasional partner in the previous 12 months/since the previous visit	✓	✓
Condom use with an occasional partner in the last anal intercourse	✓	✓
Condom use for oral sex	✓	✓
Reasons for not using condom	✓	✓
Lubricant use for anal intercourse	✓	✓
5. Alcohol and drugs
Lifetime use of alcohol or drugs before or during intercourse	✓	–
Frequency of use of alcohol or drugs before or during intercourse in the previous 12 months/since the previous visit	✓	✓
Perception of reduction in condom use due to use of alcohol or drugs	✓	✓
6. Postexposure prophylaxis
Knowledge of PEP	✓	–
Lifetime use of PEP	✓	–
Use of PEP in the previous 12 months/since the previous visit	✓	✓
7. STIs and hepatitis
Lifetime history of STI (symptoms or diagnosis)	✓	–
Symptoms of STI in the previous 12 months/since the previous visit	✓	✓
Lifetime history of STI diagnosis	✓	–
Diagnosis of STI in the previous 12 months/since the previous visit	✓	✓
Immunisation status for hepatitis A and hepatitis B	✓	✓
Lifetime history of hepatitis virus A, B or C diagnosis	✓	✓

*Bisexual men; men with different partners; sex workers; HIV-positive men; injecting drug users; women; trios/group sex.

PEP, postexposure prophylaxis; STI, sexually transmitted infection.

Information is collected from those eligible MSM who decline to participate but agree to provide some baseline data, concerning age, gender, country of origin, educational level, HIV testing history, date and result of previous HIV test, sexual identity, screening for HIV and syphilis at the index visit to CheckpointLX, and reasons for declining participation. Questionnaires are identified through a sequential number, and each participant is identified with a six-digit and four-letter unique code corresponding to their date of birth (YYMMDD), and the first two letters of their first and last names, which allows for data linkage during follow-up while protecting personal identity.9 Periodically, questionnaires are sent to ISPUP where they are processed into a computer-based data management system, and where data are stored and analysed.

Rapid HIV testing

Rapid testing for HIV-1 and HIV-2 is performed at each visit by the same peer counsellor who conducts the interview. From April 2011 to April 2012, two rapid tests were used, namely the Retrocheck HIV (QUALPRO DIAGNOSTICS, Goa, India; manufacturer reported sensitivity=100.00% and specificity=99.75%) and Hexagon HIV (Human GmbH, Wiesbaden, Germany; manufacturer reported sensitivity=100.00% and specificity=99.50%). Since then, only the Alere Determine HIV-1/2 (Alere Medical Co, Ltd, Chiba, Japan; manufacturer reported sensitivity=100.00% and specificity=100.0%, although some studies refer lower specificity13 14) has been used according to the instructions provided by the manufacturer. In case of a reactive test, an outpatient appointment is scheduled for every participant that accepts it at the HIV/Infectious diseases clinic at Santo António dos Capuchos Hospital in Lisbon, where a confirmatory test is performed. The peer counsellor offers to accompany the participant to that appointment. Pretest and post-test counselling is offered at every visit.

Syphilis rapid testing

Rapid testing for detection of Treponema pallidum antibodies is proposed to every individual who reports with no prior history of syphilis infection or who is unaware of a previous infection; in this instance the Alere Determine Syphilis TP (Alere Medical Co, Ltd, Chiba, Japan; manufacturer reported sensitivity=92.31% and specificity=100.00%) is used according to the instructions provided by the manufacturer. In the case of a reactive test, a medical appointment is proposed and scheduled at CheckpointLX as part of the Checklist STI clinic, where a confirmatory test is performed and treatment is prescribed, if needed.

Statistical procedures

Characteristics of participants at cohort entry were described using absolute and relative frequencies in the case of categorical variables. Medians and percentiles, 25 and 75 (P25-P75), were used to describe continuous variables. Comparisons between groups were performed using the χ2 test or Fisher's exact test when variables were categorical. For continuous variables the Mann-Whitney test was used. In data analysis, all possible answer categories are described, but the missing answers are excluded from the denominator of proportions for each item since no information at all was provided. This is due to the fact that the question was not asked or not recorded in the questionnaire form. The ‘rather not say’ answers were included in the denominator since they provide valid information reported by the participants.

Characteristics of enrolled population between April 2011 and February 2014

Between April 2011 and February 2014, there were 3301 potential eligible individuals, 195 (5.9%) of whom had a HIV reactive test at entry and therefore were not included in the cohort. The remaining 3106 were eligible to the cohort. Among those, 923 (29.7%) declined to participate, and 2183 (70.3%) were enrolled in the cohort. As of February 2014, 804 of the 2183 participants had been re-evaluated at least once, yielding approximately 2300 questionnaires (figure 1). The most common reasons for declining participation were having no interest in the study (25.7%), not having the time (23.5%) and not living in Portugal (18.0%). No additional information was collected on this topic.

Figure 1

Flow chart of enrolments between April 2011 and February 2014.

As summarised in table 2, there were significant differences between participants and those who declined to participate: participants self-identified more frequently as homosexual (83.9% vs 78.3%, p<0.001); participants were more frequently born in Portugal (75.7% vs 59.0%, p<0.001); and 58.1% of participants had a university degree compared with 51.4% among those who declined to participate. The proportion of individuals who had a previous HIV test was similar between groups (81.9% in participants vs 83.8% in those who declined to participate).

Table 2

Comparison of sociodemographic characteristics between participants in the cohort and those who declined to participate

	Participants	Declined to participate	p Value
	2183 (70.3)	923 (29.7)
Sexual identity, n (%)			<0.001
Homosexual	1831 (83.9)	709 (78.3)
Bisexual	306 (14.0)	151 (16.7)
Heterosexual	28 (1.3)	37 (4.1)
Other/did not know/rather not say	17 (0.8)	8 (0.9)
Missing	1	18
Age, median (P25-P75)	29 (23–36)	30 (24–38)	0.074
Country/region of origin, n (%)			<0.001
Portugal	1573 (75.7)	539 (59.0)
Brazil	231 (11.1)	160 (17.5)
Other European country	139 (6.7)	141 (15.4)
African country	89 (4.3)	27 (3.0)
Other American country	31 (1.5)	30 (3.3)
Asia/Middle East/Oceania	9 (0.4)	16 (1.8)
Rather not say	5 (0.2)	1 (0.1)
Missing	106	9
Educational level, n (%)			<0.001
Basic education or less	78 (3.6)	101 (11.3)
Secondary education	564 (25.9)	288 (32.3)
Professional training	260 (11.9)	36 (4.0)
Bachelor	896 (41.0)	341 (38.2)
Master or Doctoral	373 (17.1)	118 (13.2)
Other/rather not say	10 (0.5)	9 (1.0)
Missing	2	30
Previous HIV testing, n (%)			0.167
Yes	1650 (81.9)	766 (83.8)
No	354 (17.6)	145 (15.9)
Did not know	11 (0.5)	2 (0.2)
Rather not say	0 (0.0)	1 (0.1)
Missing	168	9

Characteristics of cohort participants

Median (P25-P75) number of HIV tests prior to cohort entry was 3 (2–6) and the most common reasons for the index HIV test were: to check health status/routine (81.3%), perception of exposure to HIV more than 3 months before (50.5%) and within the previous 3 months (40.7%; table 3).

Table 3

Characteristics related with HIV testing

HIV testing	N (%)	Missing
Previous HIV testing (n=2183)		168
Yes	1650 (81.9)
No	354 (17.6)
Did not know	11 (0.5)
Rather not say	0 (0.0)
Number of previous tests, median (P25-P75)	3 (2–6)	31
Place of last HIV test (n=1650)		2
Public network of VCT centres (CAD)	506 (30.7)
Family doctor (National health service)	311 (18.9)
Public hospital (National health service)	182 (11.0)
Abroad	152 (9.2)
Private laboratory	150 (9.1)
Private hospital or clinic	144 (8.7)
CheckpointLX	79 (4.8)
Blood donation	45 (2.7)
Mobile unit	28 (1.7)
Other	49 (3.0)
Did not know	2 (0.1)
Reasons for index test (n=2183)*
To check health status/routine	1736 (81.3)	49
Perception of HIV exposure more than 3 months before	1084 (50.5)	38
Perception of HIV exposure in the previous 3 months	884 (40.7)	9
Accident with condom use (rupture/left inside)	183 (8.6)	56
My partner asked me to test for HIV	158 (7.4)	57
To stop using condom with my partner	149 (7.0)	64
Partner diagnosed HIV+/disclosed HIV+ status	138 (6.5)	56
Possible window period by the time of the last test	136 (6.4)	61
Symptoms/medical indication	58 (2.7)	61
Other reason	159 (7.3)	–

*Percentage of participants that answered ‘yes’ at each option after excluding missing answers. The remaining participants answered no, did not know or rather not say.

CAD, Centro de Aconselhamento e Deteção Precoce do VIH; VCT, voluntary counselling and testing.

Median (P25-P75) age at first AI (receptive or insertive) was 18 (16–22) years, and 1409 (65.2%) men reported having a versatile role on AI, while 553 (25.6%) reported having only an insertive role and 177 (8.2%) only a receptive role. Twelve per cent reported sexual intercourse with HIV-positive men in the previous 12 months (table 4).

Table 4

Characteristics related with sexual life and partners

Sexual life and partners	N (%)	Missing
Age at first anal intercourse, median (P25-P75)	18 (16–22)	216
Role on anal intercourse		22
Only insertive	553 (25.6)
Only receptive	177 (8.2)
Versatile	1409 (65.2)
Did not know	2 (0.1)
Rather not say	20 (1.0)
Intercourse with at least one of the following in the previous 12 months
Bisexual men		31
Yes	732 (34.0)
No	1145 (53.2)
Did not know	262 (12.2)
Rather not say	13 (0.6)
Men with different sex partners		32
Yes	1475 (68.6)
No	491 (22.8)
Did not know	172 (8.0)
Rather not say	13 (0.6)
Sex workers (even if not paid)		32
Yes	133 (6.2)
No	1920 (89.3)
Did not know	85 (4.0)
Rather not say	13 (0.6)
HIV-positive men
Yes	259 (12.0)	32
No	1181 (54.9)
Did not know	698 (32.5)
Rather not say	13 (0.6)
Injecting drug users		32
Yes	16 (0.7)
No	1958 (91.0)
Did not know	164 (7.6)
Rather not say	13 (0.6)
Women		32
Yes	287 (13.3)
No	1851 (86.1)
Did not know	0 (0.0)
Rather not say	13 (0.6)
Trios/group sex		33
Yes	585 (27.2)
No	1549 (72.0)
Did not know	1 (0.0)
Rather not say	15 (0.7)

In the previous 12 months, 1373 (63.0%) participants had at least one steady partner, of whom 108 (7.9%) had a HIV-positive partner, 338 (24.8%) were unaware of their steady partner's HIV status and the remaining 913 (67.0%) stated that their steady partner was HIV-negative. More than half of the men who had at least one steady partner reported no condom use with the steady partner in the last sexual encounter (LSE) and approximately 72.0% reported inconsistent use over the previous 12 months. Among those in a serodiscordant relationship, 43.7% reported inconsistent use of condoms and that proportion was 71.0% among those unaware of their steady partner's HIV status (table 5).

Table 5

Characteristics related with steady partners

Steady partner	N (%)	Missing
Steady partner in the previous 12 months (n=2183)		2
Yes, one	1254 (57.5)
Yes, more than one	119 (5.5)
No	798 (36.6)
Did not know	0 (0.0)
Rather not say	10 (0.5)
HIV status of steady partner (n=1373)		11
HIV negative	913 (67.0)
HIV positive	108 (7.9)
Did not know	338 (24.8)
Rather not say	3 (0.2)
Condom use with steady partner
In the last sexual encounter (n=1373)		70
Yes	572 (43.9)
No	718 (55.1)
Did not know	5 (0.4)
Rather not say	8 (0.6)
Frequency in the previous 12 months (n=1373)		69
Always	364 (27.9)
Often/occasionally/rarely/never	931 (71.4)
Rather not say	9 (0.7)
Frequency in the previous 12 months with HIV-positive steady partner (n=108)		5
Always	57 (55.3)
Often/occasionally/rarely/never	45 (43.7)
Rather not say	1 (1.0)
Frequency in the previous 12 months with unknown HIV status steady partner (n=338)		10
Always	95 (29.0)
Often/occasionally/rarely/never	233 (71.0)
Rather not say	0 (0.0)

Sexual intercourse with at least one occasional partner in the previous 12 months was reported by 1860 (85.2%) participants and the median (P25-P75) number of partners was 4 (2–10). Twenty-one per cent of men who had at least one occasional partner reported no condom use with an occasional partner in the LSE and 46.4% reported inconsistent use in the previous 12 months. The most referred venues where participants usually met their occasional partners were the internet (72.2%), discos and gay bars (48.4%), and cruising sites (23.2%; table 6).

Table 6

Characteristics related with occasional partners

Occasional partners	N (%)	Missing
Occasional partners in the previous 12 months (n=2183)		0
Yes	1860 (85.2)
No	312 (14.3)
Rather not say	11 (0.5)
Number of occasional partners in the previous 12 months: median (P25-P75) (n=1860)	4 (2–10)	45
Being paid for sex with money or drugs in the previous 12 months (n=1860)		1
Yes	62 (3.3)
No	1796 (96.6)
Did not know	1 (0.1)
Condom use with occasional partner
In the last sexual encounter (n=1860)		124
Yes	1360 (78.3)
No	367 (21.1)
Did not know	8 (0.5)
Rather not say	1 (0.1)
Frequency in the previous 12 months (n=1860)		123
Always	925 (53.3)
Often/occasionally/rarely/never	806 (46.4)
Did not know	2 (0.1)
Rather not say	4 (0.2)
Venues used to meet occasional partners (n=1860)*
Internet	1338 (72.2)	8
Discos and gay bars	897 (48.4)	7
Cruising sites	430 (23.2)	10
Saunas	356 (19.3)	11
Gym	232 (12.6)	14
‘Dark rooms’ (including sex shops)	129 (7.0)	11
Sex clubs	92 (5.0)	10
Other	445 (23.9)	–

*Percentage of participants that answered ‘yes’ at each option after excluding missing answers. The remaining participants answered no, did not know or rather not say.

Condoms were always used for oral sex by 2.3% of participants. Always using condoms for AI in lifetime was reported by 652 (32.9%) participants. Among the 1318 (66.5%) participants who reported not having always used condoms for AI, the most common reasons for engaging in unprotected AI were a steady partner (66.2%), a steady partner after testing negative for HIV (47.9%), ‘reliable’ persons (39.8%) and being too aroused (37.1%; table 7).

Table 7

Characteristics related with condom use

Condoms	N (%)	Missing
Lifetime condom use on oral sex (n=2183)		7
Always	49 (2.3)
Often/occasionally/rarely/never	2106 (96.8)
Rather not say	21 (1.0)
Lifetime condom use on anal intercourse (n=2183)		202
Always	652 (32.9)
Often/occasionally/rarely/never	1318 (66.5)
Rather not say	11 (0.6)
Reasons for not using condom on anal intercourse (n=1318)*
With steady partner	870 (66.2)	3
With steady partner after testing for HIV and both were negative	629 (47.9)	5
With a ‘reliable’ person	523 (39.8)	3
Being too aroused	487 (37.1)	6
Condom reduces pleasure	360 (27.4)	5
With a partner who declares he is HIV negative	303 (23.1)	7
Not having condoms at that moment	261 (19.9)	5
If the participant has used alcohol or drugs	226 (17.2)	5
Condom interrupts sexual intercourse	201 (15.3)	5
Does not like using condoms	205 (15.6)	5
Condom makes the participant lose erection	188 (14.3)	4
With a partner who does not want to use	124 (9.4)	5
Being in a sex venue without condoms available	59 (4.5)	6
Condoms are expensive	40 (3.0)	6
With a partner who declares undetectable viral load†	19 (9.5)	5
Allergy to latex	24 (1.8)	6
Other reasons	77 (5.8)	–

*Percentage of participants that answered ‘yes’ at each option after excluding missing answers. The remaining participants answered no, did not know or rather not say.

†Among men who have sex with men who reported sexual intercourse with HIV-positive men in the previous 12 months.

Lifetime use of alcohol (regardless of the amount) or drugs before or during intercourse was reported by 1520 (69.7%) participants, and 1262 (59.5%) reported consumption in the previous 12 months. The most frequently reported psychoactive substances were alcohol (57.6%), poppers (17.8%) and cannabis (15.9%; table 8).

Table 8

Characteristics related with alcohol and drug use before or during intercourse

Alcohol and drugs	N (%)	Missing
Lifetime use of alcohol or drugs before or during intercourse (n=2183)		1
Yes	1520 (69.7)
No	662 (30.3)
Use of alcohol or drugs before or during intercourse in the previous 12 months (n=2183)		62
Yes	1262 (59.5)
No	837 (39.4)
Did not know	4 (0.2)
Rather not say	19 (0.9)
Ever used alcohol or drugs before or during intercourse in the previous 12 months (n=2183)*
Alcohol	1256 (57.6)	4
Poppers	389 (17.8)	2
Cannabis	329 (15.9)	114
Cocaine	236 (10.8)	1
Ecstasy	123 (5.6)	3
Viagra/cialis/similar	89 (4.1)	2
Mephedrone	76 (3.5)	3
Amphetamines	72 (3.3)	3
GHB	37 (1.7)	2
Ketamine	32 (1.5)	2
LSD	31 (1.4)	3
Heroin	7 (0.3)	3
Methadone	8 (0.4)	2
Others	49 (2.2)	–

*Percentage of participants that answered ‘yes’ at each option after excluding missing answers. The remaining participants answered no, did not know or rather not say.

GHB, gamma-hydroxybutyric acid; LSD, lysergic acid diethylamide.

A little over one-third of participants had heard about PEP, and 54 participants (2.7%) knew about and had used PEP (table 9).

Table 9

Characteristics related with PEP

PEP (n=2183)	N (%)	Missing
Did not know about PEP	1228 (61.2)	175
Knows but never used	726 (36.2)
Knows and used	54 (2.7)

PEP, postexposure prophylaxis.

A lifetime history of STI symptoms or diagnoses was reported by 37.1% of respondents; and 9.9% reported STI symptoms/diagnoses in the past 12 months. The most commonly reported STI in the past 12 months was gonorrhoea (2.5%), followed by syphilis (1.7%). In total, 0.5% of respondents reported a lifetime history of hepatitis C diagnosis (none of whom reported injection drug use; table 10).

Table 10

Characteristics related with STIs

STIs and hepatitis	N (%)	Missing
Lifetime history of STI (symptoms or diagnosis) (n=2183)		6
Yes, in the previous 12 months	216 (9.9)
Yes, more than 12 months before	593 (27.2)
No	1368 (62.8)
STI diagnosed (n=2183)
History of gonorrhoea		3
Yes, in the previous 12 months	57 (2.5)
Yes, more than 12 months before	169 (7.8)
No	1946 (89.3)
Did not know	8 (0.4)
History of syphilis		1
Yes, in the previous 12 months	38 (1.7)
Yes, more than 12 months before	116 (5.3)
No	2026 (92.9)
Did not know	2 (0.1)
History of condyloma or genital warts		3
Yes, in the previous 12 months	68 (3.1)
Yes, more than 12 months before	22 (1.0)
No	2088 (95.6)
Did not know	2 (0.1)
History of chlamydia		2
Yes, in the previous 12 months	64 (2.9)
Yes, more than 12 months before	14 (0.6)
No	2096 (96.1)
Did not know	7 (0.3)
History of genital herpes		3
Yes, in the previous 12 months	4 (0.2)
Yes, more than 12 months before	21 (1.0)
No	2153 (98.8)
Did not know	2 (0.1)
History of Trichomonas		1
Yes, in the previous 12 months	3 (0.1)
Yes, more than 12 months before	1 (0.0)
No	2176 (99.7)
Did not know	2 (0.1)
History of lymphogranuloma venereum		1
Yes, in the previous 12 months	0 (0.0)
Yes, more than 12 months before	2 (0.1)
No	2178 (99.8)
Did not know	2 (0.1)
Lifetime history of hepatitis diagnosis (n=2183)		12
History of hepatitis A
Yes	127 (5.8)
No	1897 (87.4)
Did not know	137 (6.3)
Rather not say	10 (0.5)
History of hepatitis B		13
Yes	52 (2.4)
No	2002 (92.3)
Did not know	106 (4.9)
Rather not say	10 (0.5)
History of hepatitis C		15
Yes	10 (0.5)
No	2032 (93.7)
Did not know	116 (5.4)
Rather not say	10 (0.5)
Vaccination (n=2183)		8
Hepatitis A
Yes	827 (38.0)
No	742 (34.1)
Did not know	596 (27.4)
Rather not say	10 (0.5)
Hepatitis B		6
Yes	1603 (73.6)
No	312 (14.3)
Did not know	252 (11.6)
Rather not say	10 (0.5)

STI, sexually transmitted infection.

Strengths and limitations

The Lisbon Cohort of MSM is the first Portuguese prospective study of MSM in the context of HIV incidence and testing. As an open prospective study, it will provide information on the trends of HIV infection and other STIs among MSM in Portugal, and it will contribute to identify and monitor determinants of infection, including risk-taking behaviours.

Until recently, serological and behavioural evidence relating to HIV among MSM in Portugal was scarce, apart from the necessarily succinct indicators obtained through routine national HIV surveillance. Two recent cross-sectional studies15 16 targeting MSM in Portugal provided the first population-based estimates of self-reported prevalence among MSM with a previous HIV test: 10.9%6 and 10.3% (Gama A, 2013, personal communication). In addition to these alarming estimates, both studies have raised important concerns regarding the future of the epidemic in Portugal supporting the need for closer monitoring of behavioural and serological indicators within a dynamic framework.

A few cohorts follow HIV-negative MSM internationally with different recruitment strategies and settings. For instance, the Amsterdam Cohort Studies (ACS) on HIV infection and AIDS, which started shortly after the first cases of AIDS had been diagnosed in the Netherlands,17 and the Multicenter AIDS Cohort Study (MACS), initiated in 1983 in four universities in the USA;18 both are based at formal health or academic facilities. The Omega Cohort Study in Montreal, Canada, was carried out from October 1996 to July 2003 at formal health facilities and at community organisations.19 The Health in Men (HIM) in Sydney, Australia, was established in July 200120 and, recently, in 2008, The ITACA cohort–HIV negative MSM cohort study for early diagnosis of HIV and other STIs and their determinants was established in Barcelona. Both of these are community-based open cohorts.21 These cohorts have significantly contributed to our understanding of the HIV/AIDS epidemic, and the HIM and ITACA cohorts, especially, will enable comparisons of their findings with those of our newly developed infrastructure. Additionally, the Lisbon Cohort of MSM has the potential to serve as a modern decentralised surveillance structure that will provide dynamic information about the frequency of the disease and its determinants in this group. Within our geographical setting, this study has the potential to enable locally adapted responses in terms of service provision, namely on the development of effective strategies to anticipate diagnosis. The cohort will also allow for comparisons of behavioural indicators drawn from entry and follow-up questionnaires within the international context, since it collects the set of indicators for behavioural surveillance among MSM defined by the European Centre for Disease Control and Prevention (ECDC).22 Finally, a set of specific analytical research objectives will be pursued, with strong emphasis on how contextual and behavioural trajectories throughout follow-up may be used to predict the risk of seroconversion.

The Lisbon Cohort of MSM has a relevant strength in the peer-based approach provided by CheckpointLX. Peer-based services attempt to promote an adequate response to MSM needs, to be non-judgemental and inclusive, which has been reported as the preference of gay and other MSM for testing services.23 From a research point of view, we believe this approach can also help in reducing social desirability bias with regard to the information collected, and can be more cost-effective than interventions based on clinical staff.24 Another strength of the cohort is the assurance of anonymity, which is expected to influence completeness of reporting and disclosure of risk.9 Furthermore, CheckpointLX peer counsellors accompany newly identified HIV-positive participants to their first appointment at a HIV/Infectious disease clinic to boost linkage to care. This strategy is in common with that of other community-based centres dedicated to MSM in European countries that have shown to have high efficiency in HIV detection and linkage to care.25 26

The Lisbon Cohort of MSM, as a facility-based structure, is unlikely to result in a representative sample of the source MSM population, which limits the generalisability of our findings to the whole community. This is a frequent concern in studies with non-probabilistic samples, but it should not be used as an argument for not attempting to generate the best scientific evidence possible within real-world constraints. In addition, by following only MSM who actively seek HIV testing, we are arguably selecting a subgroup that might be on average at a higher risk of infection than the general MSM community. Consequently, this focuses our attention onto a priority subset of the population (even if potentially more aware than those not reached by the service). The following comparisons are useful to assess the extent of selection bias (table 11). In the 2007 National Health and Sexuality Survey (HSS),27 which included a representative sample of the Portuguese population, 4.7% of adult male individuals reported some kind of sexual contact with other men in their lifetime, 3.0% of sexually active men had sex with men in the previous 12 months, and 0.9% reported homosexual identity. Despite the heteronormative frame still persistent in Portuguese society,27 the proportion of men reporting sex with other men is quite similar to that estimated by Marcus et al, where approximately 3.0% of the adult male population living in Portugal were estimated to be MSM.28 Men in our sample are clearly younger than in the HSS, where about 31% were less than 25 years old, whereas men who have had some kind of sexual contact with men in that age strata represent only 9.8% in the HSS. Men in the Lisbon Cohort reported more frequently of having had a previous HIV test (81.9% vs 61.0% in HSS). When compared with the European MSM internet survey results15 from a subanalysis including only participants aged 18 or more living in the Lisbon region, men in our sample have lower median age (29 vs 32) and lower educational level (58.1% with an university degree vs 61.9%), but report homosexual identity more frequently (83.9% vs 73.6%), previous HIV test (81.9% vs 77.0%) and lifetime use of PEP (2.7% vs 2.1%).

Table 11

Comparison of the Lisbon Cohort of MSM with previous studies in Portugal

	Lisbon Cohort of MSM	HSS*	EMIS Portugal†
Age
Median (P25-P75)	29 (23–36)	Not available	32 (25–40)
Up to 24 (%)	30.9	9.8	28.0
University degree (%)	58.1	Not available	61.9
Self-reported homosexual identity (%)	83.9	35.9	73.6
HIV previous test (%)	81.9	61.0	77.0
Lifetime use of PEP (%)	2.7	Not available	2.1

*Between only those men who have had some kind of sexual contact with men.

†Subanalysis of participants aged 18 years or more living in the Lisbon region.

EMIS, European men who have sex with men internet survey; HSS, Health and Sexuality Survey; MSM, men who have sex with men; PEP, postexposure prophylaxis.

We may assume that we are capturing men who are more self-identified as homosexual, which was expected once CheckpointLX was targeted to this group, and perhaps more aware of HIV risk as the frequency of uptake of HIV testing is higher than in the previous studies. It is important to stress that since CheckpointLX promotion strategies remained similar during follow-up, we do not expect a change in the extent of selection bias over time, which is particularly important for the estimation of secular trends of infection and behaviours in the source population.8–10

Participation bias is also a key methodological issue in epidemiological studies. In fact, participants in our study are more self-identified as homosexual, more frequently born in Portugal and more educated than those who declined to participate. This implies that important data may be missing on a harder to reach subset of the target population. However, it is interesting to note that the proportion of a previous HIV test is similar between groups, suggesting that both groups may have similar perceived high risk of acquiring HIV.29 30

Attrition is a main concern in prospective investigations; due to the fact that this is not an interval cohort with fixed follow-up times, the ability to estimate attrition in a short time frame is limited. However, efforts have been made in order to minimise dropout rates. CheckpointLX peer counsellors ask all participants to provide their email or mobile phone contact details on their first visit and to update their contact details in the follow-up assessments. These details are then used, with the consent of the participants, in order to send reminders within the month of an intended follow-up.

One other ongoing challenge is the possible behavioural modification by cohort participants due to their participation in an investigation, known as the Hawthorne effect. This aspect also relates to the dual role of CheckpointLX as a healthcare/counselling provider and research structure. Checkpoint's first priority is that appropriate and high-quality pretest and post-test information or counselling is offered, and hopefully that will produce a change towards better health empowerment, likely to influence the risk of the outcomes being studied.31

Collaboration

We invite scientists, researchers and students from graduation or postgraduation to get involved in data collection and/or analyses, and to raise new scientific questions in the scope of the Lisbon Cohort of MSM. Requests for data analysis, presentation or publication, must be submitted to the Lisbon Cohort of MSM scientific coordination, and will require acknowledgement that Lisbon Cohort of MSM has the property of the data. Information is available at http://www.checkpointLX.com.